[HTML][HTML] Receptor tyrosine kinase inhibitors for the treatment of recurrent and unresectable bone sarcomas
V Albarrán, ML Villamayor, J Chamorro… - International Journal of …, 2022 - mdpi.com
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
V Albarrán, ML Villamayor, J Chamorro… - International …, 2022 - search.proquest.com
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
V Albarrán, ML Villamayor… - International …, 2022 - search.ebscohost.com
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
[HTML][HTML] Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
V Albarrán, ML Villamayor, J Chamorro… - … Journal of Molecular …, 2022 - ncbi.nlm.nih.gov
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
V Albarrán, ML Villamayor, J Chamorro… - … Journal of Molecular …, 2022 - europepmc.org
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
[PDF][PDF] Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
V Albarrán, ML Villamayor, J Chamorro… - Int. J. Mol …, 2022 - pdfs.semanticscholar.org
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
V Albarrán, ML Villamayor, J Chamorro, DI Rosero… - 2022 - agris.fao.org
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
V Albarrán, ML Villamayor… - International …, 2022 - pubmed.ncbi.nlm.nih.gov
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
V Albarrán, ML Villamayor, J Chamorro, DI Rosero… - Int. J. Mol. Sci, 2022 - europepmc.org
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …
young population. Few options of systemic treatment are available once they become …